Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

Pfizer Inc.’s stock rose handily Tuesday after the drug manufacturer said it’s trending toward the higher end of its 2025 profit projections. Pfizer also beat analyst expectations for first ...

Intel Corp. Chief Executive Lip-Bu Tan seems to be making interesting moves early in his tenure, but that doesn’t mean he’ll achieve success easily. The company has missed out on the ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other most profitable cheap stocks to buy. US stocks rose on Friday, May 2, as the S&P 500 ...

Pfizer's CEO said tariff uncertainty is hindering the company from making big investments in the US. Albery Bourla said there could be "tremendous investments" in R&D and manufacturing in the US ...

The stock closed at $5.17 on April 29, 2025, and was trading down 2.32% in pre-market activity on April 30, suggesting investors remain cautious about the company’s turnaround prospects despite ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it ...

Other drugmakers are eyeing the market as well. Pfizer (NYSE: PFE) is certainly in that group. However, the company finds itself at a distinct disadvantage after it recently threw in the towel on ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top ...

Irish staff of drug giant Pfizer are waiting to hear whether another round of cost-cutting, announced on Tuesday, will mean more job losses at the group’s Irish operations. Pfizer said it will ...

Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and ...